Roche on Monday revealed positive results from the EMBARK trial, showing that its gene therapy Elevidys has sustained benefits for individuals with Duchenne muscular dystrophy (DMD) over a two ...

Sarepta Therapeutics hits 52-week lows despite strong earnings and growth. Read why investors should view SRPT as a high risk ...

(RTTNews) - Sarepta Therapeutics, Inc. (SRPT) Monday reported positive topline results from Part 2 of the Phase 3 study, dubbed EMBARK, of its gene therapy Elevidys approved for the treatment of ...

The EMBARK study of Elevidys (delandistrogene moxeparvovec) was designed to support the expansion of the label for the recently approved gene therapy to include all ambulatory DMD patients ...

Roche announced positive topline results from year two of the EMBARK trial, a global, randomised, double-blind phase III study of Elevidys (delandistrogene moxeparvovec), the first approved gene ...

The outcome of the review was not certain, given that Elevidys was unable to meet its primary objective in the phase 3 EMBARK study reported last year, with a non-significant increase compared to ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported ...

Tazeen Ahmad’s rating is based on the recent positive results from Sarepta Therapeutics’ EMBARK study ... treated with Elevidys. The study’s two-year data revealed statistically significant ...

Gil Blum has given his Buy rating due to a combination of factors surrounding the positive outcomes from Sarepta Therapeutics’ EMBARK study ... the potential of Elevidys as a treatment.

Sarepta reported topline results from Part 2 of EMBARK (Study SRP-9001-301), a Phase 3 clinical study of ELEVIDYS (delandistrogene moxeparvovec-rokl), the only approved gene therapy for Duchenne ...